Introduction
Although the incidence of lung adenocarcinoma has increased in never and former smokers, women, and young adults, the role of gender in risk remains unresolved (1).
Interestingly, breast cancer patients receiving antiestrogens for breast cancer had lower lung cancer mortality, indicating a possible role for estrogens in disease progression (2) . We reported that lung adenocarcinoma cell lines from females respond proliferatively to estradiol (E 2 ) and were inhibited by estrogen receptor (ER) antagonists 4-hydroxytamoxifen (4-OHT) or ICI 182,780 (ICI, Fulvestrant) (3) . In contrast, lung adenocarcinoma cells from males were neither stimulated by E 2 nor blocked by 4-OHT or ICI. Similar responses were detected when examining E 2 -induced cyclin D1 (CCND1) transcription (3) . ERα and ERβ expression was similar among cell lines from males and females, indicating that the observed phenotype was not due to lower ER in cells from males. Other investigators detected E 2 -induced proliferation and activation of intracellular MAPK and PI3K by ERα, ERβ, GPR30, and epidermal growth factor receptor (EGFR) in lung adenocarcinoma cell lines in a gender-independent manner (4, 5).
Mucin1 (MUC1) is a high MW plasma membrane (PM)-bound protein with a heavily O-
glycosylated N-terminal domain (NTD) that protrudes from the apical surface of glandular epithelial cells in lung, breast, and colon (6) . MUC1 has a single transmembrane domain and a 72 aa C-terminal domain (CD) that is cleaved and regulated by tyrosine phosphorylation (7) .
MUC1 is a marker of type II pneumocyte progenitor cell lineage (8) . MUC1 surface expression is critical for the protective function of the airway epithelium (9) . A MUC1 gene polymorphism for the large MUC1 allele was associated with lung adenocarcinoma but not with squamous cell carcinoma (10) . MUC1 is an oncogene (11) , increased in lung cancer (12) , and is a clinical marker for lung adenocarcinoma (13) . During dedifferentiation in lung adenocarcinoma progression, MUC1 is reduced and mislocalizes to the entire PM where it blocks cell-cell and cell-matrix adhesion, allowing tumor cell invasion (14) . The NTD is secreted by tracheobronchial epithelial cells and is a mucus component (15) .
Within cells, MUC1-CD interacts with proteins including PI3K, Shc, PLC1, c-Src, Grb-2, p53, IKKβ, IKKγ, β-catenin, hsp90, hsp70, and ERα (7) . MUC1 overexpression in cancer cells results in MUC1-CD nuclear and mitochondrial localization (16) . MUC1-CD interacts with ERα in the nucleus of breast cancer cells where it increased ERα-transcriptional activity (17) .
Since MUC1 is an oncogene, it makes a tempting therapeutic target (18) . MUC1 knockdown by siRNA in A549 lung adenocarcinoma cells increased sensitivity to cisplatin (19) .
Similarly, stable transfection of siMUC1 inhibited H358 non-small cell lung cancer (NSCLC) tumor formation in mice (20) . Treatment of breast cancer cells with a MUC1 inhibitory peptide (MIP) cloned adjacent to the protein transduction domain (PTD4) created a peptide called PMIP that is taken up by cells without transfection reagents (21) . PMIP acts as a decoy for MUC1 binding partners. PMIP inhibited MUC1/β-catenin and MUC1/EGFR interactions and inhibited MDA-MB-231 breast cancer cell proliferation, migration, and invasion in vitro and tumor growth in mice (21) . Similarly, a MUC1 inhibitor called GO-201 bound MUC1-CD, blocked MUC1 oligomerization and induced necrosis in MCF-7, ZR-75-1, and MDA-MB-231 breast cancer cells (16) . GO-201 was recently reported to inhibit the proliferation of lung adenocarcinoma cell lines (22) .
This study tested the hypotheses that ERα and ERβ interact functionally with MUC1 in lung adenocarcinoma cells and that PMIP selectively inhibits lung adenocarcinoma, not normal human bronchial epithelial cells (HBECs), proliferation and inhibits ER-responses. 
Materials and Methods

Chemicals
Estrogen receptor
Recombinant human ERα and ERβ1 (long form) were prepared as described (23).
Cell Culture
The 5 HBEC cell lines, their maintenance and characterization were described (23, 24) and HBECs were used at passages < 8. MCF-7 cells were purchased from ATCC and used at passages < 10 from ATCC. MCF-7 were maintained as described (3) . Prior to treatment, cells were placed in phenol red-free media supplemented with 5% dextran-coated charcoal stripped FBS (DCC-FBS) for 24-48 h. Ethanol (EtOH) was the vehicle control. PCR primers to detect the MUC1 splice variants MUC1/A and MUC1/B were P1 and P2 (25) .
Products were analyzed on a DNA 500 chip of the Agilent 2100 Bioanalyzer. 
Immunofluorescence imaging
Protein Isolation
Whole cell extracts (WCE) were prepared in modified RIPA buffer (3) . Protein concentrations were determined using the Bio-Rad DC Protein Assay (Bio-Rad Laboratories).
Western blotting
Western analysis was performed as described (3) . The membranes were stripped and reprobed for α-tubulin. Immunoblots were scanned using a Microtek ScanMaker VII scanner. Un-Scan-It was divided by concordant α-tubulin IOD in the same blot. For comparison between experiments, the MUC1 CD/α-tubulin normalized pixel ratios for MCF-7 cells was set to 1.
Coimmunoprecipitation
Nuclear lysates were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents Luciferase and Renilla luciferase activities were determined using Promega's Dual Luciferase assay and calculations were performed (3).
RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR)
RNA was extracted from cells using Trizol (Invitrogen) or RNeasy (Qiagen). The High Capacity cDNA archive kit (PE Applied Biosystems) was used to reverse transcribe total RNA using random hexamers. QRT-PCR for MUC1 used ABI Taqman primers (27) and was normalized by 18S rRNA. Analysis and fold differences were determined using the comparative CT method.
Data are presented as relative to expression in EtOH-treated and control transfected cells.
miRNA Isolation and QRT-PCR
miRNA-enriched total RNA was extracted from MCF-7, H1793, and H23 cells using the miRNA isolation kit (Exiqon). The quality and quantity of the isolated RNA was analyzed using a NanoDrop spectrophotometer and Agilent Bioanalyzer. cDNA was synthesized using the miRCURY LNA TM first strand cDNA synthesis kit and QPCR performed using the miRCURY LNA TM SYBR Green master mix using the miRNA primer sets for miR-125b and -145 (Exiqon).
5S rRNA was used for normalization of miRNA expression. Analysis and fold change was determined using the comparative CT method. The change in miRNA expression was calculated as fold-change, i.e., relative to MCF-7 cells.
Statistical Analysis
Statistical analyses were performed using Student's t-test or one-way ANOVA followed by Student-Newman-Keuls or Dunnett's post-hoc tests using GraphPad Prism. 
MUC1 splice variants in lung adenocarcinoma cells and HBECs
Although MUC1 is used as a clinical marker for lung adenocarcinoma (13, 30) , to our knowledge, no one has examined MUC1 splice variants in lung adenocarcinomas or cell lines derived from lung tumors. RT-PCR was performed to detect MUC1/A and MUC1/B splice variants (31) . The results indicate no apparent gender-dependent difference in MUC1/A or MUC1/B splice variant expression (Supplemental Table 1 ), although a larger population would be needed to confirm these data.
Total MUC1 mRNA expression was evaluated using a primer set that recognizes all variants of MUC1 (Fig. 1D ) and a primer set that recognizes only MUC1B (Fig. 1E ). Previous investigators reported that E 2 increased MUC1 in MCF-7 cells (28); however, these results were based on semi-quantitative PCR that detected two MUC1 bands, one of which the authors called a precursor form, and no quantitation of the single point experiment was performed. Here protein than H23, we anticipated lower miR-125b and miR-145 in MCF-7 and H1793 cells relative to H23. MCF-7 has higher miR-125b and miR-145 than either H1793 or H23 cells ( Fig.   2A and B) . The lower miR-145 expression in H1793 relative to H23 suggests that miR-145 may reduce MUC1 protein in H23 cells. To test this idea, H23, H1793, and MCF-7 were transfected with control AS and AS-miR-145 and MUC1 protein was examined by western blot (Fig. 2C) .
Supplemental Fig. 2 shows that AS-miR-145 reduced miR-145 and that neither the AS control or mock transfection affected miR-145 in any cell line. However, AS-miR-145 had no effect on MUC1 protein, indicating that the miR-145 is not responsible for the lack of MUC1 in H23 cells and does not regulate MUC1 in H1793 or MCF-7 cells.
MUC1 interacts with ERα and ERβ in lung adenocarcinoma cell lines
Since MUC1 interacts with ERα in the nucleus of MCF-7 cells (17) (Fig. 4A ).
PMIP-FITC was distributed throughout the cell with greater nuclear uptake at 4 and 24 h compared to 1 h and no apparent difference in immunofluorescence signal between 4 and 24 h.
PMIP inhibits H1793 cell proliferation
To determine if PMIP inhibits cell proliferation, H23, H1793, HBEC2-KT, and HBEC4-KT were treated with control peptide (CP) or PMIP (Fig. 4B) . Since PMIP inhibited MDA-MB-231 breast tumor xenograft growth in mice (21), MDA-MB-231 cell viability was determined in parallel and was inhibited in a concentration-dependent manner ( IC 50 = 1.5 μM). Notably, H1793, but not H23, HBEC2-KT, or HBEC3-KT, cells were selectively inhibited by PMIP ( Fig.   4B and C, IC 50 = ~ 0.1 μM). These data correspond to the relative MUC1 protein in each cell line (Fig. 1) . E 2 reduced the PMIP inhibition of cell viability (Fig. 4D) , but not completely. PMIP did not synergize with inhibition of cell viability by ER antagonists 4-OHT or ICI 182,780 (Fig. 4D) .
PMIP inhibits ER-activated gene transcription in H1793 cells
Because MUC1 was reported to be an ERα coactivator in MCF-7 cells (17), we examined if PMIP inhibited ER-mediated transcription in H1793 cells (Fig. 5A) . PMIP did not affect basal luciferase activity, but significantly inhibited E 2 -induced ERE-driven luciferase activity indicating that endogenous MUC1 plays a role in ER-mediated transcription in H1793 cells. E 2 increases cyclin D1 (CCND1) (23, 34) and NRF-1 (NRF1) (36) transcription in H1793 cells. Here we found that 10 μM PMIP inhibited E 2 -induced CCND1 and NRF-1 transcription (Fig. 5B and C) , a result in agreement with PMIP inhibition of cell viability (Fig. 4B) .
PMIP affects MUC1, ERα, and ERβ intracellular location in a time-dependent manner
To examine how PMIP affected the intracellular localization of MUC1 in H1793 cells, cells were treated with 10 μM PMIP for 1, 4, or 24 h (Fig. 6A) . Treatment with PMIP increased MUC1 nuclear localization with 1 and 4 h treatment. After 24 h of PMIP, MUC1 was detected in the nucleus and cytoplasm. Notably, colocalization of ERα and ERβ with MUC1 is seen in the merged images (Fig. 6A and B) . We also examined MUC1 and PMIP intracellular localization (Supplemental Fig. 4 ). MUC1 and PMIP were colocalized at all time points.
We examined how PMIP affects ERα and ERβ cellular distribution in H1793 cells ( Fig.   6A and B) . ERα was predominantly cytoplasmic in the absence of any treatment and there was an increase in nuclear ERα with 4 h PMIP treatment followed by a return to the cytoplasmic localization at 24 h PMIP treatment (Fig. 6A) . In contrast, ERβ was primarily nuclear in the absence of PMIP treatment and 1 h of PMIP increased ERβ nuclear intensity (Fig. 6B) .
However, 4 and 24 h of PMIP resulted in ERβ translocation from the nucleus to the cytoplasm (Fig. 6B) . Treatment of H1793 cells with 10 nM E 2 for 4 h increased nuclear MUC1 (Supplemental Fig. 4B ). E 2 did not alter the reduction in nuclear ERα seen in H1793 cells treated with PMIP (Fig. 6C) . These data are in agreement with PMIP's inhibition of E 2 -activated CCND1 and NRF1 transcription (Fig. 5B and C) . Interestingly, 75 of 107 H1793 cells analyzed after PMIP + E 2 treatment showed ERβ retention in the nucleus (Fig. 6C) . These data indicate that E 2 reduces the PMIP-mediated distribution of ERβ from the nucleus to the cytoplasm in ~ 70 % of cells. ERα and ERβ colocalize with PMIP ( Fig. 6C and D) , reflecting the colocalization of ERα and ERβ with MUC1 ( Fig. 6A and B) .
Discussion
Since MUC1 is an oncogene and its overexpression is a marker for reduced survival of lung adenocarcinoma patients (37) , inhibiting MUC1 function has become an important target for therapeutic intervention (18) . At the same time, MUC1, when appropriately expressed on the apical surface, is important for normal lung function and protective mucus production (38) .
Inhibition of MUC1 reduced MDA-MB-231 xenograft tumor growth in (16, 21) . Here we used the MUC1 inhibitory peptide PMIP created by Schroder's group to be taken up by cells without any sort of transfection (21) . Similar to that study, we found that H1793 and H23 cells took up 
cell lines (3) and MUC1 is an ERα coactivator in MCF-7 cells (17), here we examined ER-MUC1 interaction and inhibition by PMIP in lung adenocarcinoma cells.
We report that MUC1 protein expression is higher in 4 lung adenocarcinoma cell lines from females than 4 cell lines from males. MUC1 in the top 10% of overexpressed genes in lung cancer (www.oncomine.org). The factors regulating MUC1 expression appear to be cell-type specific. E 2 and tamoxifen increased the secreted MUC1 isoform transcription via ERα activation in breast cancer cells (29) , but E 2 did not increase MUC1 in human endometrial cancer cells (42) . We did not detect E 2 regulation of MUC1 mRNA in any lung adenocarcinoma cells, HBECs, or MCF-7 cells and conclude that E 2 does not regulate MUC1 in these cells. The difference between our results and those reported earlier in MCF-7 cells (29) is that we used Q-PCR rather than a MUC1-promoter-reporter and non-quantitative PCR. While the samples size is small, we observed no significant difference in MUC1/A and MUC1/B splice variant expression between lung adenocarcinoma cell lines derived from female versus male patients.
Exploring gender-or disease-specific associations with MUC1 splice variant expression requires a large sample size and is a separate project.
As reported for MCF-7 cells (17) unknown in lung, future studies to identify ERβ-MUC1-regulated genes in lung cancer will be informative.
Given the higher MUC1 protein in H1793 compared to H23, we were surprised to find comparable MUC1 mRNA. Although H23 expresses both MUC1/A and MUC1/B variants whereas H1793 express only MUC1/A, the variant is in the NTD which is in the extracellular space (31) . There are no reports regarding differential mRNA stability of MUC1 and only 3 reports on miRNA regulation of MUC1 (32, 33, 46) . 
